Rosetta Genomics develops microRNA-based molecular diagnostics. Rosetta’s research platform, which combines bioinformatics and state-of-the-art laboratory processes, has led to the discovery of hundreds of biologically-validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on applying these technologies to the development of microRNA-based diagnostic tools. Rosetta also offers cancer testing services through its Philadelphia-based CAP-accredited, CLIA-certified lab. For more information, visit the company’s website at www.rosettagenomics.com.